Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

Phase I trial of preoperative intratumoral injection of immature dendritic cells and OK-432 for resectable pancreatic cancer patients.

Endo H, Saito T, Kenjo A, Hoshino M, Terashima M, Sato T, Anazawa T, Kimura T, Tsuchiya T, Irisawa A, Ohira H, Hikichi T, Takagi T, Gotoh M.

J Hepatobiliary Pancreat Sci. 2012 Jul;19(4):465-75. doi: 10.1007/s00534-011-0457-7.

PMID:
21983893
2.
3.

In vivo immunological antitumor effect of OK-432-stimulated dendritic cell transfer after radiofrequency ablation.

Nakagawa H, Mizukoshi E, Iida N, Terashima T, Kitahara M, Marukawa Y, Kitamura K, Nakamoto Y, Hiroishi K, Imawari M, Kaneko S.

Cancer Immunol Immunother. 2014 Apr;63(4):347-56. doi: 10.1007/s00262-013-1514-7. Epub 2014 Jan 3.

PMID:
24384836
4.

Anti-tumor effect of an intratumoral administration of dendritic cells in combination with TS-1, an oral fluoropyrimidine anti-cancer drug, and OK-432, a streptococcal immunopotentiator: involvement of toll-like receptor 4.

Ahmed SU, Okamoto M, Oshikawa T, Tano T, Sasai A, Kan S, Hiroshima T, Ohue H, Moriya Y, Ryoma Y, Saito M, Sato M.

J Immunother. 2004 Nov-Dec;27(6):432-41.

PMID:
15534487
5.

The feasibility and safety of immunotherapy with dendritic cells loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resection of pancreatic cancer.

Morse MA, Nair SK, Boczkowski D, Tyler D, Hurwitz HI, Proia A, Clay TM, Schlom J, Gilboa E, Lyerly HK.

Int J Gastrointest Cancer. 2002;32(1):1-6.

PMID:
12630764
6.

The prognostic advantage of preoperative intratumoral injection of OK-432 for gastric cancer patients.

Gochi A, Orita K, Fuchimoto S, Tanaka N, Ogawa N.

Br J Cancer. 2001 Feb;84(4):443-51.

7.

Treatment with chemotherapy and dendritic cells pulsed with multiple Wilms' tumor 1 (WT1)-specific MHC class I/II-restricted epitopes for pancreatic cancer.

Koido S, Homma S, Okamoto M, Takakura K, Mori M, Yoshizaki S, Tsukinaga S, Odahara S, Koyama S, Imazu H, Uchiyama K, Kajihara M, Arakawa H, Misawa T, Toyama Y, Yanagisawa S, Ikegami M, Kan S, Hayashi K, Komita H, Kamata Y, Ito M, Ishidao T, Yusa S, Shimodaira S, Gong J, Sugiyama H, Ohkusa T, Tajiri H.

Clin Cancer Res. 2014 Aug 15;20(16):4228-39. doi: 10.1158/1078-0432.CCR-14-0314. Epub 2014 Jul 23.

8.
9.

[Effect of endoscopic local injection of OK-432 on regional lymph nodes in gastric cancer patients].

Ogawara T, Sakai K, Sekikawa T, Kouno K, Matsumoto Y.

Gan To Kagaku Ryoho. 1992 Aug;19(10 Suppl):1601-4. Japanese.

PMID:
1530316
10.

CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma.

Fukunaga A, Miyamoto M, Cho Y, Murakami S, Kawarada Y, Oshikiri T, Kato K, Kurokawa T, Suzuoki M, Nakakubo Y, Hiraoka K, Itoh T, Morikawa T, Okushiba S, Kondo S, Katoh H.

Pancreas. 2004 Jan;28(1):e26-31.

PMID:
14707745
11.

[Endoscopic preoperative intralesional injection of OK-432 in early gastric cancer].

Yamane T, Sagara Y, Suzuki G, Kasuga M, Sakita M, Fujita Y, Majima S.

Gan To Kagaku Ryoho. 1984 Apr;11(4):930-4. Japanese.

PMID:
6721507
12.
13.

Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation.

Okamoto M, Furuichi S, Nishioka Y, Oshikawa T, Tano T, Ahmed SU, Takeda K, Akira S, Ryoma Y, Moriya Y, Saito M, Sone S, Sato M.

Cancer Res. 2004 Aug 1;64(15):5461-70.

14.

A triple approach for diagnostic assessment of endoscopic ultrasound-guided fine needle aspiration in pancreatic solid masses and lymph nodes.

Lee YN, Moon JH, Kim HK, Choi HJ, Lee SH, Choi MH, Kim DC, Lee TH, Cha SW, Cho YD, Park SH.

Dig Dis Sci. 2014 Sep;59(9):2286-93. doi: 10.1007/s10620-014-3119-1. Epub 2014 Apr 16.

PMID:
24737383
15.

Immunological impact of neoadjuvant chemoradiotherapy in patients with borderline resectable pancreatic ductal adenocarcinoma.

Homma Y, Taniguchi K, Murakami T, Nakagawa K, Nakazawa M, Matsuyama R, Mori R, Takeda K, Ueda M, Ichikawa Y, Tanaka K, Endo I.

Ann Surg Oncol. 2014 Feb;21(2):670-6. doi: 10.1245/s10434-013-3390-y. Epub 2013 Dec 6.

PMID:
24310792
16.

1-MT enhances potency of tumor cell lysate-pulsed dendritic cells against pancreatic adenocarcinoma by downregulating the percentage of Tregs.

Li Y, Xu J, Zou H, Wang C.

J Huazhong Univ Sci Technolog Med Sci. 2010 Jun;30(3):344-8. doi: 10.1007/s11596-010-0354-3. Epub 2010 Jun 17.

PMID:
20556579
17.

Novel aspects of preoperative chemoradiation therapy improving anti-tumor immunity in pancreatic cancer.

Tsuchikawa T, Hirano S, Tanaka E, Matsumoto J, Kato K, Nakamura T, Ebihara Y, Shichinohe T.

Cancer Sci. 2013 May;104(5):531-5. doi: 10.1111/cas.12119. Epub 2013 Mar 31.

18.
19.

Mature dendritic cells make clusters with T cells in the invasive margin of colorectal carcinoma.

Suzuki A, Masuda A, Nagata H, Kameoka S, Kikawada Y, Yamakawa M, Kasajima T.

J Pathol. 2002 Jan;196(1):37-43.

PMID:
11748640
20.

Supplemental Content

Support Center